SeaStar Medical Holding Corporation (Nasdaq: ICU) announced its financial results for the fourth quarter and full year ended December 31, 2025, revealing significant growth in revenue and operational advancements. For the three months ended December 31, 2025, the company reported net revenue of approximately $420,000, a substantial increase from $67,000 in the same period of 2024. This growth is attributed to the expanding customer base of the QUELIMMUNE therapy, particularly among top-ranked children's hospitals in the U.S. The company also highlighted that its cost of goods sold for the quarter was $12,000, resulting in a gross profit margin exceeding 90%.

For the full year, SeaStar Medical reported total revenue of approximately $1.2 million, compared to $135,000 in 2024, marking a significant milestone as it reflects the first full year of QUELIMMUNE product sales. The company’s net loss for the fourth quarter was approximately $2.9 million, or $0.80 per share, an improvement from a net loss of $4.4 million, or $8.98 per share, in the prior year.

CEO Eric Schlorff expressed optimism about the company’s trajectory, stating, "In 2025, we broadened our customer base of top-ranked children's hospitals and advanced our pipeline with the initiation of the cardio-renal clinical trial of our selective cytopheretic device (SCD) therapy. We move into 2026 with strong momentum and key value-creating milestones that will impact our success and advance our mission to bring a potential life-saving therapy to patients."

The company also completed enrollment in the FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry and exceeded the 50% enrollment milestone in the pivotal trial of SCD therapy in adult patients with acute kidney injury (AKI). Looking ahead, SeaStar Medical anticipates broadening QUELIMMUNE adoption to include 15 additional top-ranked children's medical centers and achieving approximately $2 million in net product revenue in 2026.

Overall, SeaStar Medical's financial results and operational updates reflect a positive outlook, with the company poised for growth in the coming year as it continues to innovate and expand its market presence.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.